Analyst Price Target is $2.00
▲ +599.30% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Tonix Pharmaceuticals in the last 3 months. The average price target is $2.00, with a high forecast of $2.00 and a low forecast of $2.00. The average price target represents a 599.30% upside from the last price of $0.29.
Current Consensus is
The current consensus among 1 investment analysts is to buy stock in Tonix Pharmaceuticals.
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in New York, NY.